US20080064105A1 - Animal protein-free media for cultivation of cells - Google Patents

Animal protein-free media for cultivation of cells Download PDF

Info

Publication number
US20080064105A1
US20080064105A1 US11/980,833 US98083307A US2008064105A1 US 20080064105 A1 US20080064105 A1 US 20080064105A1 US 98083307 A US98083307 A US 98083307A US 2008064105 A1 US2008064105 A1 US 2008064105A1
Authority
US
United States
Prior art keywords
cells
protein
hydrolysate
medium
soy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/980,833
Inventor
Leopold Grillberger
Manfred Reiter
Wolfgang Mundt
Friedrich Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Baxter Healthcare Corp
Original Assignee
Baxter Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080064105(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Corp filed Critical Baxter Healthcare Corp
Priority to US11/980,833 priority Critical patent/US20080064105A1/en
Publication of US20080064105A1 publication Critical patent/US20080064105A1/en
Assigned to BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A. reassignment BAXTER INTERNATIONAL INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRILLBERGER, LEOPOLD, REITER, MANFRED, DORNER, FRIEDRICH, MUNDT, WOLFGANG
Assigned to BAXTER HEALTHCARE S.A. reassignment BAXTER HEALTHCARE S.A. CHANGE OF ADDRESS FOR ONE ASSIGNEE (ATTACHMENT NOT REQUIRED) Assignors: BAXTER HEALTHCARE SA.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0043Medium free of human- or animal-derived components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/04Plant cells or tissues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0681Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/46Amines, e.g. putrescine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/74Undefined extracts from fungi, e.g. yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/76Undefined extracts from plants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92Medium free of human- or animal-derived components

Definitions

  • the present invention relates to animal protein-free cell culture media comprising a polyamine and a plant- and/or yeast-derived hydrolysate.
  • the invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
  • FCS fetal calf serum
  • serum or serum-derived substances such as albumin, transferrin or insulin
  • human serum derived additives have to be tested for all known viruses, including hepatitis and HIV, that can be transmitted by serum.
  • bovine serum and products derived therefrom bear the risk of BSE contamination.
  • all serum-derived products can be contaminated by unknown constituents.
  • problems e.g. the varying quality in composition of the different batches and the risk of contamination with mycoplasma, viruses or BSE), particularly if the cells are used for production of drugs or vaccines for human administration.
  • Simple serum free medium typically includes basal medium, vitamins, amino acids organic or inorganic salts, and optionally additional components to make the medium nutritionally complex.
  • Soy hydrolysates are known to be useful for fermentation processes and can enhance the growth of many fastidious organisms, yeasts and fungi.
  • WO 96/26266 describes that papaic digests of soy meal are a source of carbohydrate and nitrogen and many of the components can be used in tissue culture.
  • Franek et al. (Biotechnology Progress (2000) 16, 688-692) describe growth and productivity promoting effects of defined soy hydrolysate peptide fractions.
  • WO 96/15231 discloses serum-free medium composed of the synthetic minimal essential medium and yeast extract for propagation of vertebrate cells and virus production process.
  • a medium formulation composed of a basal cell culture medium comprising a rice peptide and an extract of yeast and enzymatic digest thereof, and/or a plant lipid for growth of animal cells is disclosed in WO 98/15614.
  • a medium comprising purified soy hydrolysate for the cultivation of recombinant cells is disclosed in WO 01/23527.
  • WO 00/03000 discloses a medium that comprises a soy hydrolysate and a yeast extract, but also requires the presence of recombinant forms of animal proteins, such as growth factors.
  • EP-A-0 481 791 describes a biochemically defined culture medium for culturing engineered CHO cells, which is free from protein, lipid and carbohydrate isolated from an animal source, further comprising a recombinant insulin or insulin analogue, 1% to 0.025% w/v papain digested soy peptone and putrescine.
  • WO 98/08934 describes a serum-free eukaryotic cell culture comprising hydrolyzed soy peptides (1-1000 mg/L), 0.01 to 1 mg/L putrescine and a variety of animal-derived components, including albumin, fetuin, various hormones and other proteins.
  • putrescine is also known to be contained in standard media like DMEM/Ham's F12 in a concentration of 0.08 mg/L.
  • the media known in the state of art are often nutritionally insufficient and/or must be supplemented with animal-derived protein supplements or recombinant versions of proteins, such as insulin, insulin like growth factor or other growth factors.
  • soy peptone extracts also designated as “soy hydrolysates”
  • soy hydrolysates On the basis of soy peptone extracts (also designated as “soy hydrolysates”) media have been developed, which do not contain animal proteins.
  • soy hydrolysates the quality of commercially available lots of soy hydrolysates varies extremely and as a result, there are large variations in the production of recombinant proteins or viral products (a variation of up to a factor of 3) as a function of the lots of soy hydrolysates used (“lot-to-lot variation”). This draw back affects the proliferation of the cells as well as the protein expression of each cell.
  • An object of the present invention is to provide an animal protein-free cell culture medium which does not contain any added supplementary proteins derived from an animal source and/or recombinant animal proteins, which allows efficient cell growth and in particular protein production in a continuous quality with respect to the amount of expression per cell.
  • a further object of the present invention is to provide a method for cultivating cells and a method for efficient expression of recombinant proteins which are free of animal proteins.
  • Another object of the present invention is to reduce plant and/or yeast derived hydrolysate in order to overcome inhibitory effects which would negatively impact the production yield of a desired recombinant or viral product. Hydrolysates were surprisingly found to be the cause of the lot-to-lot variations in production.
  • the animal protein-free cell culture medium according to the invention comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate, wherein the polyamine preferably originates from a source other than the protein hydrolysate.
  • the addition of at least one polyamine, in particular the addition of putrescine, to the animal protein-free cell culture medium provides the advantageous effect not only to promote the cell growth but in particular to increase the protein expression per cell and, in particular, recombinant protein expression per cell.
  • the animal protein-free medium according to the present invention allows consistent cell growth and increased yield of desired products, particularly of target proteins such as recombinant proteins, independent of the quality or lot variations of the protein hydrolysate, in particular of the vegetable hydrolysates, in the animal protein-free cell culture medium.
  • the specific supplementation of cell culture media with polyamines and a plant- and/or yeast-derived hydrolysate acts synergistically to increase cell growth, cell specific productivity and final cell density.
  • the animal protein free medium according to the present invention is more favorable for recombinant protein expression and cell growth rate compared to the media known in the art. Furthermore, the animal protein-free medium according to the present invention allows the reduction of the amount of protein hydrolysate to be added to a given volume of the cell culture medium.
  • FIG. 2 shows a table which compares the volumetric FVIII-COA productivity of GD8/6 cells grown in media with different soy hydrolysate concentrations.
  • FIG. 3 shows a graph which compares the volumetric FVIII-CoA productivity of GD8/6 cells as a function of the media used for culture, which were supplemented with 5 different lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.25% (w/v)) (A) in the absence of putrescine and (B) in the presence of 1 mg/L putrescine.2HCl.
  • FIG. 4 shows a graph which compares the specific growth rates of GD8/6 cells as a function of the media used for culture, which were supplemented with 5 different lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.25% (w/v)) (A) in the absence of putrescine and (B) in the presence of 1 mg/L putrescine.2HCl.
  • FIG. 5 shows a table which compares the volumetric FVIII-CoA productivity (QP [U/L/D]) and the specific growth rate ( ⁇ [d-1]) of GD8/6 cells and their standard deviation grown in media with 5 different selected lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.4% (w/v) or 0.25% (w/v)) with the same soy hydrolysates (0.25% (w/v)) with and without putrescine.2HCl at 1 mg/L.
  • QP [U/L/D] volumetric FVIII-CoA productivity
  • ⁇ [d-1] specific growth rate
  • FIG. 6 shows a table which describes the average putrescine concentrations found in soy hydrolysates (0.4% (w/v) in cell culture medium) from different manufacturers.
  • FIG. 7 shows a table which compares the effect of soy hydrolysate (0.4% (w/v)) and soy hydrolysate (0.25% (w/v))+1.8 mg/L putrescine.2HCl on the volumetric productivity (QP expressed in [mg IgG1/L reactor volume/day] and cell specific productivity (qp [ ⁇ g IgG1/10E06 Cells/d]) in ARH77 cells secreting a monoclonal antibody.
  • QP expressed in [mg IgG1/L reactor volume/day]
  • cell specific productivity qp [ ⁇ g IgG1/10E06 Cells/d]
  • FIG. 8 shows a graph which compares the effect of soy hydrolysate (0.25% (w/v)) and soy hydrolysate (0.25% (w/v))+1 mg/L putrescine (1.8 mg/L putrescine.2HCl) on the cell specific erythropoeitin (EPO)-productivity of recombinant BHK cells (EPO production (Units)/glucose consumption (g).
  • EPO erythropoeitin
  • FIG. 9 shows a table comparing the effect of putrescine, omithine and spermine over a wider concentration range (0-18 mg/L) on the specific growth ( ⁇ absolute, ⁇ relative) and the cell specific productivity (Qp absolute, Qp relative) of GD8/6 cells cultivated in BAV-medium containing 0.0% soy hydrolysate and no amines, or BAV-medium containing a reduced soy hydrolysate concentration of 0.25% supplemented with polyamines in the concentration range indicated above.
  • One aspect of the invention relates to an animal protein-free cell culture medium comprising at least one polyamine and a plant- and/or yeast-derived hydrolysate, in a concentration sufficiently reduced in order to avoid potential inhibitory effects of the hydrolysate.
  • polyamine refers to any of a group of organic compounds composed of carbon, nitrogen, and hydrogen, and containing two or more amino groups.
  • the term encompasses molecules selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, and ornithine.
  • the concentration of the polyamine is present in a concentration ranging from about 0.5 mg/L to about 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium.
  • the total concentration of the plant- and/or yeast-derived protein hydrolysate in the animal protein-free cell culture medium is about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v); i.e. if the medium contains a plant- and a yeast derived protein hydrolysate, the total concentration is calculated by the summing up the concentration values of each of the protein hydrolysate components contained in the medium.
  • animal protein free cell culture medium refers to a medium that does not contain proteins and/or protein components from higher multicellular non-plant eukaryotes. Typical proteins that are avoided are those found in serum and serum-derived substances, such as albumin, transferrin, insulin and other growth factors.
  • the animal protein free cell culture medium is also free of any purified animal derived products and recombinant animal derived products as well as protein digests and extracts thereof or lipid extracts or purified components thereof.
  • Animal proteins and protein components are to be distinguished from non-animal proteins, small peptides and oligopeptides obtainable from plants (usually 10-30 amino acids in length), such as soy bean, and lower eukaryotes, such as yeast which may be included into the animal protein free cell culture medium according to the invention.
  • the animal protein free culture medium according to the invention may be based on any basal medium such as DMEM, Ham's F12, Medium 199, McCoy or RPMI generally known to the skilled worker.
  • the basal medium may comprise a number of ingredients, including amino acids, vitamins, organic and inorganic salts, and sources of carbohydrate, each ingredient being present in an amount which supports the cultivation of a cell which is generally known to the person skilled in the art.
  • the medium may contain auxiliary substances, such as buffer substances like sodium bicarbonate, antioxydants, stabilizers to counteract mechanical stress, or protease inhibitors.
  • a non-ionic surfactant such as mixtures of polyethylene glycols and polypropylene glycols (e.g. Pluronic F68®, SERVA) can be added as a defoaming agent.
  • the polyamine employed for the animal protein free culture medium according to the invention may be selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, omithine, and combinations thereof. Most preferably, the animal protein free culture medium contains omithine, putrescine and spermine.
  • the polyamine controls DNA- and RNA-synthesis, cell proliferation, cell differentiation, membrane stabilization, and/or antioxidative DNA-protection.
  • Putrescine, spermidine, spermine, and omithine are examples of polyamines which exhibit these functions.
  • Another example of a polyamine is cadaverine.
  • the polyamine originates from a source other than the protein hydrolysate.
  • the polyamine is present in a concentration ranging from about 0.5 to about 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium, and the plant- and/or yeast-derived protein hydrolysate is present in the medium in a concentration ranging from about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v).
  • the plant-derived protein hydrolysate used for the animal protein-free cell culture medium according to the invention is preferably selected from the group consisting of a cereal hydrolysate and/or a soy hydrolysate.
  • the soy hydrolysate may be a highly purified soy hydrolysate, a purified soy hydrolysate or crude soy hydrolysate.
  • hydrolysate includes any enzymatic digest of a vegetable or yeast extract.
  • the “hydrolysate” can be further enzymatically digested, for example by papain, and/or formed by autolysis, thermolysis and/or plasmolysis.
  • Hydrolysates to be used according to the present invention are also commercially available, such as HyPep 1510®, Hy-Soy®, Hy-Yeast 412® and Hi-Yeast 444®, from sources such as Quest International, Norwich, N.Y., OrganoTechnie, S.A. France, Irish Hefewerke GmbH, Germany, or DMV Intl. Delhi, N.Y.
  • Sources of yeast extracts and soy hydrolysates are also disclosed in WO 98/15614, WO 00/03000, WO 01/23527 and U.S. Pat. No. 5,741,705.
  • the hydrolysates are preferably purified from crude fraction, because impurities could interfere with efficient cultivation. Purification can be carried out by ultrafiltration or Sephadex chromatography, for example with Sephadex 25 or Sephadex G10 or equivalent materials, ion exchange chromatography, affinity chromatography, size exclusion chromatography or reverse-phase-chromatography.
  • the fractions may contain hydrolysates of defined molecular weight, preferably up to about 1000 Dalton, more preferably up to about 500 Dalton, most preferably up to about 350 Dalton. At least about 90% of the hydrolysate has preferably a molecular weight of up to about 1000 Dalton.
  • the average molecular weight of the hydrolysates lies preferably between about 220 and about 375 Daltons.
  • the pH value of the hydrolysate should be in the range of from about 6.5 to about 7.5.
  • the total nitrogen content is preferably between about 5 and about 15%, and the ash content is preferably up to about 20%.
  • the free amino acid content is preferably between about 5% and about 30%.
  • the endotoxin content is preferably less than about 500 U/g.
  • the invention also provides a method of using at least one polyamine for addition to an animal protein-free cell culture medium containing a plant- and/or yeast-derived protein hydrolysate, for increasing the protein expression yield in the cultured cells.
  • the polyamine is present in the culture medium in a total concentration ranging from about 0.5 to about 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium.
  • the polyamine is selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, omithine, and combinations thereof.
  • the plant- and/or yeast-derived protein hydrolysate is present in the medium in a concentration ranging from about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v).
  • the present invention further relates to a method for cultivating cells, comprising the steps of:
  • the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate.
  • the polyamine originates from a source other than the protein hydrolysate.
  • the present invention is not limited to any type of cells.
  • the cells used are for example mammalian cells, insect cells, avian cells, bacterial cells, yeast cells.
  • the cells may be for example stem cells or recombinant cells transformed with a vector for recombinant gene expression, or cells transfected with a virus for producing viral products.
  • the cells may also be for example cells producing a protein of interest without recombinant transformation, e.g. a B-cell producing an antibody, which may be transformed into an immortalized status e.g. by viral infection like Epstein Barr Virus infection.
  • the cells may also be for example primary cells, e.g. chicken embryo cells, or primary cell lines. Preferred are cells that are used for in vitro virus production.
  • the cells may be BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, CHO cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, RK cells, and chicken embryo cells.
  • the cells used according to the present invention may be cultivated by a method selected from the group of batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostate-cultivation all of which are generally known in the field.
  • the present invention further relates to a method for expressing a target protein such as a heterologous or autologous protein or a recombinant protein, comprising the steps of:
  • the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate.
  • the polyamine originates from a source other than the protein hydrolysate.
  • the nucleic acid sequence comprising a sequence coding for the target protein may be a vector.
  • the vector may be a virus or a plasmid.
  • the sequence coding for a target protein may be a specific gene or a biological functional part thereof.
  • the target protein is at least a biologically active part of a blood coagulation factor such as the Factor VIII or at least a biologically active part of a protein involved in the production of red blood cells and angiogenesis such as erythropoeitin, or a monoclonal antibody.
  • the nucleic acid further comprises other sequences suitable for controlled expression of a target protein such as promotor sequences, as enhancers, TATA boxes, transcription initiation sites, polylinkers, restriction sites, poly-A-sequences, protein processing sequences, selection markers, and the like which are generally known to the person skilled in the art.
  • promotor sequences as enhancers, TATA boxes, transcription initiation sites, polylinkers, restriction sites, poly-A-sequences, protein processing sequences, selection markers, and the like which are generally known to the person skilled in the art.
  • CHO cells for the production of recombinant coagulation factor VIII
  • BHK cells for the production of recombinant erythropoietin
  • Epstein Barr virus transformed immortalized human B cells for the production of human antibodies.
  • the present invention further relates to a method for producing a virus or part of a virus, comprising the steps of:
  • the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate. More preferably, the polyamine originates from a source other than the protein hydrolysate.
  • the virus used in the method according to the invention may be any pathogenic virus, mammalian, preferably human virus, such as a vaccinia or attenuated vaccinia virus, e.g. for smallpox vaccines, coronavirus, preferably SARS virus, e.g. for production of SARS vaccines, orthomyoxyvirus, preferably influenza virus, e.g. for production of influenza vaccines, paramyxovirus, retrovirus, influenza A or B virus, Ross River virus, flavivirus, preferably West Nile virus or FSME virus (i.e. tick borne encephalitis virus), e.g. for the production of the respective vaccines, picornavirus, arena virus, herpesvirus, poxvirus or adenovirus.
  • a vaccinia or attenuated vaccinia virus e.g. for smallpox vaccines, coronavirus, preferably SARS virus, e.g. for production of SARS vaccines, orthomyoxyvirus, preferably influenza virus
  • the virus may be a wild-type-virus, an attenuated virus, a reassortant virus, or a recombinant virus or combinations thereof, e.g. attenuated and recombinant.
  • an infectious nucleic acid clone may be used instead of actual virions being used to infect cells with a virus.
  • Split virions may also be used instead of actual virions being used to infect cells with a virus.
  • the method for expressing a protein or producing a virus may be used for producing immunogenic compositions comprising a virus or a virus antigen.
  • the cells used for the method for producing a virus may be selected from the group consisting of mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells.
  • the cells are cultivated by a method selected from the group consisting of batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostat-cultivation.
  • Preferred combinations of cells with viruses for producing a virus or part of a virus are Vero cell/attenuated vaccinia, Vero cell/Vaccinia, Vero cell/Hepatitis A, Vero cell/Influenza Virus, Vero cell/West Nile Virus, Vero cell/SARS Virus, chicken embryo cells/FSME virus.
  • the present invention further relates to a method of using the animal protein-free cell culture medium according to the invention for culturing cells expressing a target protein.
  • Animal protein free medium was prepared with basal DMEM/HAM's F12 (1:1) medium supplemented with inorganic salts, amino acids, vitamins and other components (Life technologies, 32500 Powder). Also added were L-glutamine (600 mg/L), ascorbic acid (20 ⁇ M), ethanol amine (25 ⁇ M), Synperonic® (SERVA) (0.25 g/L), sodium selenite (50 nM). Additionally, essential amino acids were supplemented to the cell culture medium. Further, varying concentrations of soy hydrolysate (Quest Technologies, NY or DMV Intl., NY ) in the range of 0.0-1.0% and varying concentrations of polyamines (0-10 mg/L) were added ( FIG. 1-9 )
  • Cell cultures of recombinant mammalian cells were grown in suspension in a chemostat culture in 10 l bioreactors.
  • the culture conditions of 37° C., oxygen saturation 20% and pH 7.0 to 7.1 were kept constant.
  • the cultures were supplied with a constant feed of BAV-medium as defined in Example 1 additionally supplemented with soy hydrolysates in the range of 0.1-1.0% and/or addition of putrescine.2HCl in the range of 0-1 mg/L (cf. FIG. 1-5 ).
  • Factor VIII Factor VIII
  • FIGS. 1 to 5 and 9 The activity of Factor VIII (FVIII) was measured by a chromogenic assay (Chromogenic, Sweden).
  • the volumetric productivity is calculated from the amount of activity units or antigen titers yielded per liter reactor volume per day (U/L/d or mg/L/d) in the respective production systems.
  • the cell specific productivity is defined as the specific amount of produced protein (U or ⁇ g) per number of cells per day (cf. FIGS. 7 and 9 ) or as the specific amount of produced protein (U) produced per amount of D-glucose consumed by the cells (cf. FIG. 8 ).
  • GD8/6 cells were supplied with BAV-medium containing 0.4% (w/v) of different soy hydrolysate lots.
  • the volumetric FVIII-productivity varied from about 600 to 1800 U/L/d and the specific growth rates varied of from 0.35 to 0.52 ⁇ [d- 1 ] between the different lots (cf. FIG. 1 ). This indicates that the soy hydrolysate lots at the 0.4% concentration does not allow consistent growth of the GD8/6 cells, possibly due to inhibitory substances affecting the specific growth rate ( ⁇ ) which are contained in the soy hydrolysates.
  • GD8/6 cells were supplied with BAV-medium containing different concentrations of soy hydrolysate lot M022257 (in the range of 0.15-1.0% w/v).
  • the volumetric FVIII-productivity varied of from 500 to 1.100 U/L/d and reached an optimum productivity of 1.100 U/L/d at a soy hydrolysate concentration of 0.4% (w/v) (cf. FIG. 2 ).
  • GD8/6 cells were supplied with BAV-medium containing 0.25% (w/v) of the same 5 different soy hydrolysate lots as described in Example 5 ( FIGS. 3A and 4A ) and 0.25% (w/v) soy hydrolysate of the same soy hydrolysate lots additionally supplemented with 1 mg/L putrescine.2 HCl ( FIGS. 3B and 4B ), respectively.
  • the volumetric FVIII-productivity varied of from 1700 U/L/d to 500 U/L/d in the cells grown BAV-SP medium containing 0.25% (w/v) soy hydrolysate of different soy hydrolysate lots ( FIG. 3A ).
  • the specific growth rate varied of from 0.58 to 0.24 ⁇ [d- 1 ], indicating that the reduction of the soy hydrolysate concentration does not lead to an improved or more consistent growth rate of the cells ( FIG. 4A ).
  • putrescine to animal protein-free cell culture media not only promotes protein expression rate of cultured cells but it also reduces the amount of plant hydrolysate to be included into the culture media in order to obtain the same cell growth.
  • culture media become less affected by the lot-by-lot variation of quality of plant hydrolysate and thus an overall improvement of the cell culture conditions is achieved.
  • FIG. 5 comprises the statistical analysis of the Examples shown in FIG. 1, 2 and 4 : GD8/6 cells were supplied with BAV-medium containing 0.4% (w/v) of soy hydrolysate or 0.25% (w/v) soy hydrolysate or 0.25% (w/v) soy hydrolysate and 1 mg/L putrescine.2HCl. Standard deviations are calculated based on five selected lots of soy hydrolysates (K119-1, K138-1, M022963, M024423, M022453).
  • volumetric and cell specific FVIII-productivity and the specific growth rate with 0.25% (w/v) soy hydrolysate was lower than with 0.4% (w/v) soy hydrolysate, which confirms the optimum depicted in FIG. 2 .
  • the volumetric and cell specific FVIII-productivity and the specific growth rate increases in cell culture medium containing 0.25% (w/v) soy hydrolysate+1 mg/L putrescine.2HCl.
  • Examples 7 and 8 show that putrescine is an active compound supporting cell growth and, more specifically protein expression. Therefore, the concentration of putrescine from different soy hydrolysate lots from 2 different suppliers (Quest and DMV) were quantitatively analyzed by a HPLC method and evaluated statistically. The concentration in the cell culture media prepared with soy hydrolysate from both suppliers was approximately 2.3 mg/L putrescine, when soy hydrolysate was added to the medium in a concentration of 0.4% (w/v) (cf. FIG. 6 ).
  • ARH77 cells human lymphoblastoid cell line stably expressing hIgG
  • BAV medium 0.4% (w/v) of soy hydrolysate or 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl.
  • Arithmetic means and standard deviations were calculated from data points representing the steady states for the respective medium formulations.
  • the volumetric hIgG-volumetric productivity/cell specific productivity in BAV-medium supplemented with 0.4% (w/v) soy hydrolysate was lower than in BAV-medium supplemented with 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl.
  • This experiment indicates that the medium composition according to the present invention is capable to promote also the expression of monoclonal antibodies from a transformed cell line. Further, the specific medium composition can also be used in perfusion cultures (cf. FIG. 7 ).
  • Recombinant BHK cells were grown to confluence in 5% (v/v) fetal calf serum containing medium. The cells were washed with protein-free medium and incubated for 3 days in BAV medium supplemented with 0.25% (w/v) soy hydrolysate or 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl ( FIG. 8 ). Since no cell counting in this experiment was performed, the glucose consumption rate (g/L) was measured over three days to prove equivalent biomass in the culture system. The EPO-activity (mU/ml) was correlated with the glucose consumption rate (g/L) over three days.

Abstract

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.

Description

    FIELD OF THE INVENTION
  • The present invention relates to animal protein-free cell culture media comprising a polyamine and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
  • BACKGROUND OF THE INVENTION
  • For cultivation of cells, particularly eukaryotic cells, and more specifically mammalian cells, there is a constant need to use special culture media that make available the growth nutrient substances that are required for efficient growth of the cells and for the production of the proteins or viruses that are desired. For the efficient production of biological products, such as viruses or recombinant proteins, it is important that an optimal cell density is achieved as well as the protein expression itself is increased to obtain maximal product yield.
  • Cell culture media formulations have been supplemented with a range of additives, including undefined components like fetal calf serum (FCS), several animal derived proteins and/or protein hydrolysates of bovine origin.
  • In general, serum or serum-derived substances, such as albumin, transferrin or insulin, may contain unwanted agents that can contaminate the cell cultures and the biological products obtained therefrom. Furthermore, human serum derived additives have to be tested for all known viruses, including hepatitis and HIV, that can be transmitted by serum. Moreover, bovine serum and products derived therefrom bear the risk of BSE contamination. In addition, all serum-derived products can be contaminated by unknown constituents. In the case of serum or protein additives that are derived from human or other animal sources in cell culture, there are numerous problems (e.g. the varying quality in composition of the different batches and the risk of contamination with mycoplasma, viruses or BSE), particularly if the cells are used for production of drugs or vaccines for human administration.
  • Therefore, many attempts have been made to provide efficient host systems and cultivation conditions, which do not require serum or other animal protein compounds. Simple serum free medium typically includes basal medium, vitamins, amino acids organic or inorganic salts, and optionally additional components to make the medium nutritionally complex.
  • Soy hydrolysates are known to be useful for fermentation processes and can enhance the growth of many fastidious organisms, yeasts and fungi. WO 96/26266 describes that papaic digests of soy meal are a source of carbohydrate and nitrogen and many of the components can be used in tissue culture. Franek et al. (Biotechnology Progress (2000) 16, 688-692) describe growth and productivity promoting effects of defined soy hydrolysate peptide fractions.
  • WO 96/15231 discloses serum-free medium composed of the synthetic minimal essential medium and yeast extract for propagation of vertebrate cells and virus production process. A medium formulation composed of a basal cell culture medium comprising a rice peptide and an extract of yeast and enzymatic digest thereof, and/or a plant lipid for growth of animal cells is disclosed in WO 98/15614. A medium comprising purified soy hydrolysate for the cultivation of recombinant cells is disclosed in WO 01/23527. WO 00/03000 discloses a medium that comprises a soy hydrolysate and a yeast extract, but also requires the presence of recombinant forms of animal proteins, such as growth factors.
  • EP-A-0 481 791 describes a biochemically defined culture medium for culturing engineered CHO cells, which is free from protein, lipid and carbohydrate isolated from an animal source, further comprising a recombinant insulin or insulin analogue, 1% to 0.025% w/v papain digested soy peptone and putrescine. WO 98/08934 describes a serum-free eukaryotic cell culture comprising hydrolyzed soy peptides (1-1000 mg/L), 0.01 to 1 mg/L putrescine and a variety of animal-derived components, including albumin, fetuin, various hormones and other proteins. In this context, it should be also noted that putrescine is also known to be contained in standard media like DMEM/Ham's F12 in a concentration of 0.08 mg/L.
  • However, the media known in the state of art are often nutritionally insufficient and/or must be supplemented with animal-derived protein supplements or recombinant versions of proteins, such as insulin, insulin like growth factor or other growth factors.
  • Therefore, a current need exists to increase the yield of expressed recombinant protein or any other expression product, and specific growth rate of cells, and to provide an optimal cell culture medium completely free of animal proteins for production of biological products, such as those used as pharmaceuticals or vaccines in humans.
  • On the basis of soy peptone extracts (also designated as “soy hydrolysates”) media have been developed, which do not contain animal proteins. However, the quality of commercially available lots of soy hydrolysates varies extremely and as a result, there are large variations in the production of recombinant proteins or viral products (a variation of up to a factor of 3) as a function of the lots of soy hydrolysates used (“lot-to-lot variation”). This draw back affects the proliferation of the cells as well as the protein expression of each cell.
  • Therefore, there is a need for an animal protein-free cell culture medium which is completely free of animal proteins and overcomes at least one of the above-mentioned problems.
  • SUMMARY OF THE INVENTION
  • An object of the present invention is to provide an animal protein-free cell culture medium which does not contain any added supplementary proteins derived from an animal source and/or recombinant animal proteins, which allows efficient cell growth and in particular protein production in a continuous quality with respect to the amount of expression per cell. A further object of the present invention is to provide a method for cultivating cells and a method for efficient expression of recombinant proteins which are free of animal proteins.
  • Another object of the present invention is to reduce plant and/or yeast derived hydrolysate in order to overcome inhibitory effects which would negatively impact the production yield of a desired recombinant or viral product. Hydrolysates were surprisingly found to be the cause of the lot-to-lot variations in production.
  • The animal protein-free cell culture medium according to the invention comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate, wherein the polyamine preferably originates from a source other than the protein hydrolysate.
  • Surprisingly, the addition of at least one polyamine, in particular the addition of putrescine, to the animal protein-free cell culture medium provides the advantageous effect not only to promote the cell growth but in particular to increase the protein expression per cell and, in particular, recombinant protein expression per cell.
  • Further, the animal protein-free medium according to the present invention allows consistent cell growth and increased yield of desired products, particularly of target proteins such as recombinant proteins, independent of the quality or lot variations of the protein hydrolysate, in particular of the vegetable hydrolysates, in the animal protein-free cell culture medium. The specific supplementation of cell culture media with polyamines and a plant- and/or yeast-derived hydrolysate acts synergistically to increase cell growth, cell specific productivity and final cell density.
  • Therefore, the animal protein free medium according to the present invention is more favorable for recombinant protein expression and cell growth rate compared to the media known in the art. Furthermore, the animal protein-free medium according to the present invention allows the reduction of the amount of protein hydrolysate to be added to a given volume of the cell culture medium.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows a graph which compares (A) the volumetric FVIII-CoA productivity (expressed in [U/L/D]=FVIII COA Units per L reactor volume per day and (B) the specific growth rate (μ expressed in [d−1]=1 per day) of GD8/6 cells as a function of the media used for culture, which were supplemented with different lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.4% (w/v)).
  • FIG. 2 shows a table which compares the volumetric FVIII-COA productivity of GD8/6 cells grown in media with different soy hydrolysate concentrations.
  • FIG. 3 shows a graph which compares the volumetric FVIII-CoA productivity of GD8/6 cells as a function of the media used for culture, which were supplemented with 5 different lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.25% (w/v)) (A) in the absence of putrescine and (B) in the presence of 1 mg/L putrescine.2HCl.
  • FIG. 4 shows a graph which compares the specific growth rates of GD8/6 cells as a function of the media used for culture, which were supplemented with 5 different lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.25% (w/v)) (A) in the absence of putrescine and (B) in the presence of 1 mg/L putrescine.2HCl.
  • FIG. 5 shows a table which compares the volumetric FVIII-CoA productivity (QP [U/L/D]) and the specific growth rate (μ[d-1]) of GD8/6 cells and their standard deviation grown in media with 5 different selected lots (K119-1, K138-1, M022963, M024423, M022453) of soy hydrolysates (0.4% (w/v) or 0.25% (w/v)) with the same soy hydrolysates (0.25% (w/v)) with and without putrescine.2HCl at 1 mg/L.
  • FIG. 6 shows a table which describes the average putrescine concentrations found in soy hydrolysates (0.4% (w/v) in cell culture medium) from different manufacturers.
  • FIG. 7 shows a table which compares the effect of soy hydrolysate (0.4% (w/v)) and soy hydrolysate (0.25% (w/v))+1.8 mg/L putrescine.2HCl on the volumetric productivity (QP expressed in [mg IgG1/L reactor volume/day] and cell specific productivity (qp [μg IgG1/10E06 Cells/d]) in ARH77 cells secreting a monoclonal antibody.
  • FIG. 8 shows a graph which compares the effect of soy hydrolysate (0.25% (w/v)) and soy hydrolysate (0.25% (w/v))+1 mg/L putrescine (1.8 mg/L putrescine.2HCl) on the cell specific erythropoeitin (EPO)-productivity of recombinant BHK cells (EPO production (Units)/glucose consumption (g).
  • FIG. 9 shows a table comparing the effect of putrescine, omithine and spermine over a wider concentration range (0-18 mg/L) on the specific growth (μ absolute, μ relative) and the cell specific productivity (Qp absolute, Qp relative) of GD8/6 cells cultivated in BAV-medium containing 0.0% soy hydrolysate and no amines, or BAV-medium containing a reduced soy hydrolysate concentration of 0.25% supplemented with polyamines in the concentration range indicated above. BAV-SP 0.25%=BAV medium containing 0.25% soy hydrolysate; BAV-SP 0.4%=BAV medium containing 0.4% soy hydrolysate; BAV w/o soy no polyamines=BAV medium containing neither soy hydrolysate nor polyamines.
  • DETAILED DESCRIPTION OF THE INVENTION
  • One aspect of the invention relates to an animal protein-free cell culture medium comprising at least one polyamine and a plant- and/or yeast-derived hydrolysate, in a concentration sufficiently reduced in order to avoid potential inhibitory effects of the hydrolysate.
  • The term “polyamine” refers to any of a group of organic compounds composed of carbon, nitrogen, and hydrogen, and containing two or more amino groups. For example, the term encompasses molecules selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, and ornithine.
  • Unless stated differently, concentration values indicated throughout this document refer to the free base form of the component(s).
  • In a preferred embodiment of the animal protein-free cell culture medium the concentration of the polyamine is present in a concentration ranging from about 0.5 mg/L to about 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium.
  • In a preferred embodiment the total concentration of the plant- and/or yeast-derived protein hydrolysate in the animal protein-free cell culture medium is about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v); i.e. if the medium contains a plant- and a yeast derived protein hydrolysate, the total concentration is calculated by the summing up the concentration values of each of the protein hydrolysate components contained in the medium.
  • The term “animal protein free cell culture medium” according to the invention refers to a medium that does not contain proteins and/or protein components from higher multicellular non-plant eukaryotes. Typical proteins that are avoided are those found in serum and serum-derived substances, such as albumin, transferrin, insulin and other growth factors. The animal protein free cell culture medium is also free of any purified animal derived products and recombinant animal derived products as well as protein digests and extracts thereof or lipid extracts or purified components thereof. Animal proteins and protein components are to be distinguished from non-animal proteins, small peptides and oligopeptides obtainable from plants (usually 10-30 amino acids in length), such as soy bean, and lower eukaryotes, such as yeast which may be included into the animal protein free cell culture medium according to the invention.
  • The animal protein free culture medium according to the invention may be based on any basal medium such as DMEM, Ham's F12, Medium 199, McCoy or RPMI generally known to the skilled worker. The basal medium may comprise a number of ingredients, including amino acids, vitamins, organic and inorganic salts, and sources of carbohydrate, each ingredient being present in an amount which supports the cultivation of a cell which is generally known to the person skilled in the art. The medium may contain auxiliary substances, such as buffer substances like sodium bicarbonate, antioxydants, stabilizers to counteract mechanical stress, or protease inhibitors. If required, a non-ionic surfactant such as mixtures of polyethylene glycols and polypropylene glycols (e.g. Pluronic F68®, SERVA) can be added as a defoaming agent.
  • The polyamine employed for the animal protein free culture medium according to the invention may be selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, omithine, and combinations thereof. Most preferably, the animal protein free culture medium contains omithine, putrescine and spermine.
  • In an preferred embodiment of the animal protein free culture medium the polyamine controls DNA- and RNA-synthesis, cell proliferation, cell differentiation, membrane stabilization, and/or antioxidative DNA-protection. Putrescine, spermidine, spermine, and omithine are examples of polyamines which exhibit these functions. Another example of a polyamine is cadaverine.
  • In another preferred embodiment of the animal protein-free cell culture medium according to the invention the polyamine originates from a source other than the protein hydrolysate.
  • In a further preferred embodiment of the animal protein-free cell culture medium the polyamine is present in a concentration ranging from about 0.5 to about 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium, and the plant- and/or yeast-derived protein hydrolysate is present in the medium in a concentration ranging from about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v).
  • The plant-derived protein hydrolysate used for the animal protein-free cell culture medium according to the invention is preferably selected from the group consisting of a cereal hydrolysate and/or a soy hydrolysate. The soy hydrolysate may be a highly purified soy hydrolysate, a purified soy hydrolysate or crude soy hydrolysate.
  • The term “hydrolysate” includes any enzymatic digest of a vegetable or yeast extract. The “hydrolysate” can be further enzymatically digested, for example by papain, and/or formed by autolysis, thermolysis and/or plasmolysis. Hydrolysates to be used according to the present invention are also commercially available, such as HyPep 1510®, Hy-Soy®, Hy-Yeast 412® and Hi-Yeast 444®, from sources such as Quest International, Norwich, N.Y., OrganoTechnie, S.A. France, Deutsche Hefewerke GmbH, Germany, or DMV Intl. Delhi, N.Y. Sources of yeast extracts and soy hydrolysates are also disclosed in WO 98/15614, WO 00/03000, WO 01/23527 and U.S. Pat. No. 5,741,705.
  • The hydrolysates are preferably purified from crude fraction, because impurities could interfere with efficient cultivation. Purification can be carried out by ultrafiltration or Sephadex chromatography, for example with Sephadex 25 or Sephadex G10 or equivalent materials, ion exchange chromatography, affinity chromatography, size exclusion chromatography or reverse-phase-chromatography. The fractions may contain hydrolysates of defined molecular weight, preferably up to about 1000 Dalton, more preferably up to about 500 Dalton, most preferably up to about 350 Dalton. At least about 90% of the hydrolysate has preferably a molecular weight of up to about 1000 Dalton. The average molecular weight of the hydrolysates lies preferably between about 220 and about 375 Daltons. The pH value of the hydrolysate should be in the range of from about 6.5 to about 7.5. The total nitrogen content is preferably between about 5 and about 15%, and the ash content is preferably up to about 20%. The free amino acid content is preferably between about 5% and about 30%. The endotoxin content is preferably less than about 500 U/g.
  • The invention also provides a method of using at least one polyamine for addition to an animal protein-free cell culture medium containing a plant- and/or yeast-derived protein hydrolysate, for increasing the protein expression yield in the cultured cells. According to a preferred embodiment of the invention, the polyamine is present in the culture medium in a total concentration ranging from about 0.5 to about 30 mg/L, more preferably from about 0.5 mg/L to about 20 mg/L, even more preferably from about 0.5 mg/L to about 10 mg/L, more preferably from about 2 mg/L to about 8 mg/L, most preferably from about 2 to about 5 mg/L in the medium. Preferably, the polyamine is selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, omithine, and combinations thereof. Preferably, the plant- and/or yeast-derived protein hydrolysate is present in the medium in a concentration ranging from about 0.05% to about 5% (w/v), more preferably about 0.05% to about 2% (w/v), more preferably about 0.05% to about 1% (w/v), more preferably about 0.05% to about 0.5% (w/v), most preferably about 0.05% to about 0.25% (w/v).
  • The present invention further relates to a method for cultivating cells, comprising the steps of:
    • (a) providing an animal protein-free cell culture medium according to the invention, and
    • (b) propagating the cells in the medium to form a cell culture.
  • In a preferred embodiment the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate. Preferably the polyamine originates from a source other than the protein hydrolysate.
  • The present invention is not limited to any type of cells. In a preferred embodiment of the invention the cells used are for example mammalian cells, insect cells, avian cells, bacterial cells, yeast cells. The cells may be for example stem cells or recombinant cells transformed with a vector for recombinant gene expression, or cells transfected with a virus for producing viral products. The cells may also be for example cells producing a protein of interest without recombinant transformation, e.g. a B-cell producing an antibody, which may be transformed into an immortalized status e.g. by viral infection like Epstein Barr Virus infection. The cells may also be for example primary cells, e.g. chicken embryo cells, or primary cell lines. Preferred are cells that are used for in vitro virus production. In a preferred embodiment the cells may be BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, CHO cells, NS-1 cells, MRC-5 cells, WI-38 cells, BHK cells, 293 cells, RK cells, and chicken embryo cells.
  • The cells used according to the present invention may be cultivated by a method selected from the group of batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostate-cultivation all of which are generally known in the field.
  • The present invention further relates to a method for expressing a target protein such as a heterologous or autologous protein or a recombinant protein, comprising the steps of:
    • a) providing a culture of cells that have been grown in an animal protein-free cell culture medium according to the invention; and
    • b) introducing a nucleic acid sequence comprising a sequence coding for the target protein into the cells;
    • c) selecting the cells carrying the nucleic acid sequence; and
    • d) selectively inducing the expression of the target protein in the cells.
  • In a preferred embodiment the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate. Preferably, the polyamine originates from a source other than the protein hydrolysate.
  • The nucleic acid sequence comprising a sequence coding for the target protein may be a vector. The vector may be a virus or a plasmid. The sequence coding for a target protein may be a specific gene or a biological functional part thereof. In a preferred embodiment the target protein is at least a biologically active part of a blood coagulation factor such as the Factor VIII or at least a biologically active part of a protein involved in the production of red blood cells and angiogenesis such as erythropoeitin, or a monoclonal antibody.
  • Preferably, the nucleic acid further comprises other sequences suitable for controlled expression of a target protein such as promotor sequences, as enhancers, TATA boxes, transcription initiation sites, polylinkers, restriction sites, poly-A-sequences, protein processing sequences, selection markers, and the like which are generally known to the person skilled in the art.
  • Most preferred are the following cell lines transformed with a recombinant vector for the expression of the respective products: CHO cells for the production of recombinant coagulation factor VIII, BHK cells for the production of recombinant erythropoietin, Epstein Barr virus transformed, immortalized human B cells for the production of human antibodies.
  • The present invention further relates to a method for producing a virus or part of a virus, comprising the steps of:
    • a) providing a culture of cells that have been grown in an animal protein-free cell culture medium according to the invention; and
    • b) infecting the cells with a virus;
    • c) selecting the virus-infected cells; and
    • d) incubating the cells to propagate the virus.
  • In a preferred embodiment the animal protein-free cell culture medium comprises at least one polyamine and a plant- and/or yeast-derived hydrolysate. More preferably, the polyamine originates from a source other than the protein hydrolysate.
  • The virus used in the method according to the invention may be any pathogenic virus, mammalian, preferably human virus, such as a vaccinia or attenuated vaccinia virus, e.g. for smallpox vaccines, coronavirus, preferably SARS virus, e.g. for production of SARS vaccines, orthomyoxyvirus, preferably influenza virus, e.g. for production of influenza vaccines, paramyxovirus, retrovirus, influenza A or B virus, Ross River virus, flavivirus, preferably West Nile virus or FSME virus (i.e. tick borne encephalitis virus), e.g. for the production of the respective vaccines, picornavirus, arena virus, herpesvirus, poxvirus or adenovirus.
  • The virus may be a wild-type-virus, an attenuated virus, a reassortant virus, or a recombinant virus or combinations thereof, e.g. attenuated and recombinant. In addition, instead of actual virions being used to infect cells with a virus, an infectious nucleic acid clone may be used. Split virions may also be used.
  • The method for expressing a protein or producing a virus may be used for producing immunogenic compositions comprising a virus or a virus antigen.
  • The cells used for the method for producing a virus may be selected from the group consisting of mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells. Preferably, the cells are cultivated by a method selected from the group consisting of batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostat-cultivation.
  • Preferred combinations of cells with viruses for producing a virus or part of a virus are Vero cell/attenuated vaccinia, Vero cell/Vaccinia, Vero cell/Hepatitis A, Vero cell/Influenza Virus, Vero cell/West Nile Virus, Vero cell/SARS Virus, chicken embryo cells/FSME virus.
  • The present invention further relates to a method of using the animal protein-free cell culture medium according to the invention for culturing cells expressing a target protein.
  • The present invention will now be further illustrated in the following examples, without being limited thereto.
  • EXAMPLES Example 1 BAV-Medium
  • Animal protein free medium was prepared with basal DMEM/HAM's F12 (1:1) medium supplemented with inorganic salts, amino acids, vitamins and other components (Life technologies, 32500 Powder). Also added were L-glutamine (600 mg/L), ascorbic acid (20 μM), ethanol amine (25 μM), Synperonic® (SERVA) (0.25 g/L), sodium selenite (50 nM). Additionally, essential amino acids were supplemented to the cell culture medium. Further, varying concentrations of soy hydrolysate (Quest Technologies, NY or DMV Intl., NY ) in the range of 0.0-1.0% and varying concentrations of polyamines (0-10 mg/L) were added (FIG. 1-9)
  • Example 2
  • Cell cultures of recombinant mammalian cells (e.g. CHO-cells stably expressing Factor VIII=GD8/6-cells) were grown in suspension in a chemostat culture in 10 l bioreactors. The culture conditions of 37° C., oxygen saturation 20% and pH 7.0 to 7.1 were kept constant. The cultures were supplied with a constant feed of BAV-medium as defined in Example 1 additionally supplemented with soy hydrolysates in the range of 0.1-1.0% and/or addition of putrescine.2HCl in the range of 0-1 mg/L (cf. FIG. 1-5).
  • Small scale experiments with GD8/6 cells in suspension culture were carried in Techne spinner flasks at 200 ml working volume in batch refeed mode at 37° C., without pH and pO2 control. The cultures were supplied with BAV-medium as defined in Example 1 without supplementation of soy hydrolysate and polyamines, or supplemented with soy hydrolysate in the range of 0.1-0.4% and/or putrescine.2HCl, omithine.HCl, spermine.4HCl in the range of 0-18 mg/L (equivalent to 0-10 mg/L of the polyamine without .HCl (cf. FIG. 9).
  • Example 3 cf. FIGS. 1 to 5 7, and 9
  • Cell counts from suspension cells or immobilized cells were determined either by counting with a CASY® cell counter as described by Schärfe et al., (Biotechnologie in LaborPraxis 10: 1096-1103 (1988)) or by citric acid extraction and flourescent staining of the nuclei followed by counting with a NucleoCounter® (Chemometec, DK). The specific growth rate (μ) is calculated from the increase of the cell densities (Xt) and/or the dilution rate (D) of the steady state of chemostat cultures of suspensions cells over a certain time interval (t):
    μ=D+In(Xt/X0)/t
  • Example 4
  • The activity of Factor VIII (FVIII) (cf. FIGS. 1 to 5 and 9) was measured by a chromogenic assay (Chromogenic, Sweden). The activity of erythropoeitin (cf. FIG. 8) and the monoclonal antibody titer (cf. FIG. 7) were measured by ELISA test systems.
  • The volumetric productivity is calculated from the amount of activity units or antigen titers yielded per liter reactor volume per day (U/L/d or mg/L/d) in the respective production systems.
  • The cell specific productivity is defined as the specific amount of produced protein (U or μg) per number of cells per day (cf. FIGS. 7 and 9) or as the specific amount of produced protein (U) produced per amount of D-glucose consumed by the cells (cf. FIG. 8).
  • Example 5
  • GD8/6 cells were supplied with BAV-medium containing 0.4% (w/v) of different soy hydrolysate lots. The volumetric FVIII-productivity varied from about 600 to 1800 U/L/d and the specific growth rates varied of from 0.35 to 0.52 μ[d-1] between the different lots (cf. FIG. 1). This indicates that the soy hydrolysate lots at the 0.4% concentration does not allow consistent growth of the GD8/6 cells, possibly due to inhibitory substances affecting the specific growth rate (μ) which are contained in the soy hydrolysates.
  • Example 6
  • GD8/6 cells were supplied with BAV-medium containing different concentrations of soy hydrolysate lot M022257 (in the range of 0.15-1.0% w/v). The volumetric FVIII-productivity varied of from 500 to 1.100 U/L/d and reached an optimum productivity of 1.100 U/L/d at a soy hydrolysate concentration of 0.4% (w/v) (cf. FIG. 2).
  • Example 7
  • GD8/6 cells were supplied with BAV-medium containing 0.25% (w/v) of the same 5 different soy hydrolysate lots as described in Example 5 (FIGS. 3A and 4A) and 0.25% (w/v) soy hydrolysate of the same soy hydrolysate lots additionally supplemented with 1 mg/L putrescine.2 HCl (FIGS. 3B and 4B), respectively. The volumetric FVIII-productivity varied of from 1700 U/L/d to 500 U/L/d in the cells grown BAV-SP medium containing 0.25% (w/v) soy hydrolysate of different soy hydrolysate lots (FIG. 3A). The specific growth rate varied of from 0.58 to 0.24 μ[d-1], indicating that the reduction of the soy hydrolysate concentration does not lead to an improved or more consistent growth rate of the cells (FIG. 4A).
  • In contrast, only minor variations of the volumetric FVIII-productivity (FIG. 3B) and specific growth rates (FIG. 4B) between the same soy hydrolysate lots are observed in the cells grown BAV-medium containing 0.25% (w/v) soy hydrolysate when supplemented with 1 mg/L putrescine.2HCl. The addition of 1 mg/L putrescine.2HCl approximately compensates the reduction of this polyamine by the reduction of soy hydrolysate concentration from 0.4% (w/v) to 0.25% (w/v). From this it can be concluded that not the concentration of the polyamine itself, but the addition of the polyamine in combination with the reduction of the soy hydrolysate concentrations leads to a reduction of inhibitory substances which reduce growth and productivity (see Example 5). Furthermore, the addition of putrescine also leads to an over proportional increased volumetric productivity of FVIII due to an increase of the cell specific FVIII productivity (FIG. 5).
  • Thus addition of putrescine to animal protein-free cell culture media not only promotes protein expression rate of cultured cells but it also reduces the amount of plant hydrolysate to be included into the culture media in order to obtain the same cell growth. As a result, culture media become less affected by the lot-by-lot variation of quality of plant hydrolysate and thus an overall improvement of the cell culture conditions is achieved.
  • Example 8
  • FIG. 5 comprises the statistical analysis of the Examples shown in FIG. 1, 2 and 4: GD8/6 cells were supplied with BAV-medium containing 0.4% (w/v) of soy hydrolysate or 0.25% (w/v) soy hydrolysate or 0.25% (w/v) soy hydrolysate and 1 mg/L putrescine.2HCl. Standard deviations are calculated based on five selected lots of soy hydrolysates (K119-1, K138-1, M022963, M024423, M022453). The volumetric and cell specific FVIII-productivity and the specific growth rate with 0.25% (w/v) soy hydrolysate was lower than with 0.4% (w/v) soy hydrolysate, which confirms the optimum depicted in FIG. 2. However, the volumetric and cell specific FVIII-productivity and the specific growth rate increases in cell culture medium containing 0.25% (w/v) soy hydrolysate+1 mg/L putrescine.2HCl. Further, the standard deviation calculated from five different lots of soy hydrolysates is significantly reduced (cf. FIG. 5 [QP [U/L/D]=volumetric productivity; qp [mU/106 cells/day]=cell specific productivity).
  • Example 9
  • Examples 7 and 8 show that putrescine is an active compound supporting cell growth and, more specifically protein expression. Therefore, the concentration of putrescine from different soy hydrolysate lots from 2 different suppliers (Quest and DMV) were quantitatively analyzed by a HPLC method and evaluated statistically. The concentration in the cell culture media prepared with soy hydrolysate from both suppliers was approximately 2.3 mg/L putrescine, when soy hydrolysate was added to the medium in a concentration of 0.4% (w/v) (cf. FIG. 6).
  • Example 10
  • ARH77 cells (human lymphoblastoid cell line stably expressing hIgG) were grown in a perfusion culture after immobilization on macroporous microcarriers in a 80 L stirred tank bioreactor at 37° C., pH 7.0-7.2 and pO2 20-80% air saturation, supplied with BAV medium containing 0.4% (w/v) of soy hydrolysate or 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl. Arithmetic means and standard deviations were calculated from data points representing the steady states for the respective medium formulations. The volumetric hIgG-volumetric productivity/cell specific productivity in BAV-medium supplemented with 0.4% (w/v) soy hydrolysate was lower than in BAV-medium supplemented with 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl. This experiment indicates that the medium composition according to the present invention is capable to promote also the expression of monoclonal antibodies from a transformed cell line. Further, the specific medium composition can also be used in perfusion cultures (cf. FIG. 7).
  • Example 11
  • Recombinant BHK cells were grown to confluence in 5% (v/v) fetal calf serum containing medium. The cells were washed with protein-free medium and incubated for 3 days in BAV medium supplemented with 0.25% (w/v) soy hydrolysate or 0.25% (w/v) soy hydrolysate+1.8 mg/L putrescine.2HCl (FIG. 8). Since no cell counting in this experiment was performed, the glucose consumption rate (g/L) was measured over three days to prove equivalent biomass in the culture system. The EPO-activity (mU/ml) was correlated with the glucose consumption rate (g/L) over three days. The addition of putrescine gives a 16% increase in EPO productivity compared to BAV-medium merely supplemented with 0.25% (w/v) soy peptone. This experiment also indicates that the medium composition according to the present invention is capable to promote the expression of different recombinant proteins.
  • Example 12
  • To prove the specific effect of putrescine, ornithine and spermine over a wider concentration range (0-18 mg/L equivalent to 0-10 mg/L of the polyamine without —.HCl) an experiment was carried where the GD8/6 cells were incubated in Techne spinner flasks at 1-1.5 E06 cells/ml in BAV-medium containing 0.25% and 0.4% soy hydrolysate without polyamines, and BAV-medium containing the reduced soy hydrolysate concentration of 0.25% with the polyamines in the above mentioned concentration range. All three polyamines in the investigated concentration range resulted in a significant increase of cell specific productivity (expressed in mU/106 cells/day) compared to the unsupplemented medium formulation with 0.25% soy hydrolysate, or the increased concentration of 0.4%. The increase of the cell specific productivity is clearly not correlating with an increased specific growth rate, which confirms the specific effect on the expression rate of recombinant FVIII of the GD8/6 cells (FIG. 9).

Claims (3)

1. A method for cultivating cells, comprising the steps of:
(a) providing an animal protein-free cell culture medium comprising at least one polyamine and at least one protein hydrolysate derived from the group consisting of plants and yeast, and
(b) propagating the cells in the medium to form a cell culture.
2. The method according to claim 1, wherein the cells are selected from the group consisting of mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells.
3. The method according to claim 1, wherein the cells are cultivated by a method selected from the group consisting of batch-cultivation, feed-batch-cultivation, perfusion cultivation, and chemostat-cultivation.
US11/980,833 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells Abandoned US20080064105A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/980,833 US20080064105A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/976,399 US20060094104A1 (en) 2004-10-29 2004-10-29 Animal protein-free media for cultivation of cells
US11/980,833 US20080064105A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/976,399 Division US20060094104A1 (en) 2004-10-29 2004-10-29 Animal protein-free media for cultivation of cells

Publications (1)

Publication Number Publication Date
US20080064105A1 true US20080064105A1 (en) 2008-03-13

Family

ID=35447241

Family Applications (12)

Application Number Title Priority Date Filing Date
US10/976,399 Abandoned US20060094104A1 (en) 2004-10-29 2004-10-29 Animal protein-free media for cultivation of cells
US11/858,844 Abandoned US20080009040A1 (en) 2004-10-29 2007-09-20 Animal protein-free media for cultivation of cells
US11/980,833 Abandoned US20080064105A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US11/981,373 Abandoned US20080064080A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US12/781,661 Abandoned US20110081722A1 (en) 2004-10-29 2010-05-17 Animal protein-free media for cultivation of cells
US12/965,111 Active US8440408B2 (en) 2004-10-29 2010-12-10 Animal protein-free media for cultivation of cells
US13/864,118 Active US8748156B2 (en) 2004-10-29 2013-04-16 Animal protein-free media for cultivation of cells
US14/268,859 Active US9222075B2 (en) 2004-10-29 2014-05-02 Animal protein-free media for cultivation of cells
US14/954,705 Active US9714411B2 (en) 2004-10-29 2015-11-30 Animal protein-free media for cultivation of cells
US15/598,406 Active US9809796B2 (en) 2004-10-29 2017-05-18 Animal protein-free media for cultivation of cells
US15/712,408 Active US10138461B2 (en) 2004-10-29 2017-09-22 Animal protein-free media for cultivation of cells
US16/173,420 Active US10655099B2 (en) 2004-10-29 2018-10-29 Animal protein-free media for cultivation of cells

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/976,399 Abandoned US20060094104A1 (en) 2004-10-29 2004-10-29 Animal protein-free media for cultivation of cells
US11/858,844 Abandoned US20080009040A1 (en) 2004-10-29 2007-09-20 Animal protein-free media for cultivation of cells

Family Applications After (9)

Application Number Title Priority Date Filing Date
US11/981,373 Abandoned US20080064080A1 (en) 2004-10-29 2007-10-30 Animal protein-free media for cultivation of cells
US12/781,661 Abandoned US20110081722A1 (en) 2004-10-29 2010-05-17 Animal protein-free media for cultivation of cells
US12/965,111 Active US8440408B2 (en) 2004-10-29 2010-12-10 Animal protein-free media for cultivation of cells
US13/864,118 Active US8748156B2 (en) 2004-10-29 2013-04-16 Animal protein-free media for cultivation of cells
US14/268,859 Active US9222075B2 (en) 2004-10-29 2014-05-02 Animal protein-free media for cultivation of cells
US14/954,705 Active US9714411B2 (en) 2004-10-29 2015-11-30 Animal protein-free media for cultivation of cells
US15/598,406 Active US9809796B2 (en) 2004-10-29 2017-05-18 Animal protein-free media for cultivation of cells
US15/712,408 Active US10138461B2 (en) 2004-10-29 2017-09-22 Animal protein-free media for cultivation of cells
US16/173,420 Active US10655099B2 (en) 2004-10-29 2018-10-29 Animal protein-free media for cultivation of cells

Country Status (16)

Country Link
US (12) US20060094104A1 (en)
EP (5) EP2213724B2 (en)
JP (1) JP4847962B2 (en)
KR (1) KR101043547B1 (en)
CN (1) CN101065480B (en)
AU (1) AU2005299040B2 (en)
CA (1) CA2585518A1 (en)
DK (4) DK2213725T4 (en)
ES (4) ES2394746T3 (en)
HK (2) HK1147110A1 (en)
MX (1) MX2007005132A (en)
PL (4) PL2213724T3 (en)
PT (4) PT2218776E (en)
RU (1) RU2383616C2 (en)
SI (3) SI2213724T1 (en)
WO (1) WO2006045438A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100011901A1 (en) * 2008-07-16 2010-01-21 Intuitive Surgical, Inc. Four-cable wrist with solid surface cable channels

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2790887T3 (en) 2006-01-04 2020-10-29 Baxalta Inc Cell culture medium without oligopeptides
US8058049B2 (en) 2006-06-20 2011-11-15 Transgene S.A. Process for producing poxviruses and poxvirus compositions
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201708537A (en) 2006-09-13 2017-03-01 艾伯維有限公司 Cell culture improvements
JPWO2008047596A1 (en) * 2006-10-18 2010-02-25 不二製油株式会社 Freezing-resistant yeast
WO2008154014A2 (en) * 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
DK2250251T3 (en) 2008-01-09 2018-01-22 Sartorius Stedim Cellca Gmbh Improved culture medium additive and method of using it
US9458422B2 (en) * 2008-01-25 2016-10-04 University Of Maryland Composition of matter and method for stimulating the growth of beneficial microorganisms
WO2009132195A1 (en) * 2008-04-23 2009-10-29 Michigan State University Immortal avian cell line and methods of use
TW201012930A (en) 2008-06-16 2010-04-01 Intervet Int Bv Method of replicating viruses in suspension
DK2268823T3 (en) * 2008-08-28 2011-10-03 Novartis Ag Preparation of squalene from hyper-producing yeasts
CN104974251A (en) 2008-10-20 2015-10-14 Abbvie公司 Viral inactivation during purification of antibodies
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
ES2547881T5 (en) 2008-11-12 2019-10-16 Baxalta Inc Production method of serum-free and insulin-free factor VII
KR101737645B1 (en) 2008-12-30 2017-05-18 박스알타 인코퍼레이티드 Method of enhancing cell growth using alkyl-amine-n-oxide (aanox)
CN101851608B (en) * 2009-03-31 2012-09-05 北京清大天一科技有限公司 Method for producing rabies viruses by suspension culture of BHK21 cells
CN102549145B (en) 2009-07-31 2015-05-20 巴克斯特国际公司 Cell culture medium for adamts protein expression
KR20210054598A (en) 2009-09-21 2021-05-13 다케다 야쿠힌 고교 가부시키가이샤 Stabilized liquid and lyophilized adamts13 formulations
AU2011274467B2 (en) * 2010-07-08 2015-01-15 Takeda Pharmaceutical Company Limited Method of producing recombinant high molecular weight vWF in cell culture
EA032336B1 (en) 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Stable aqueous immunoglobulin composition and method of stabilization thereof
EP2632479B1 (en) 2010-10-27 2017-06-14 Baxalta GmbH Fviii peptides for immune tolerance induction and immunodiagnostics
CN102127525B (en) * 2010-12-27 2013-06-05 吉林亚泰生物药业股份有限公司 Adaption method of influenza virus vaccine strains on Vero cells
KR102007997B1 (en) 2011-02-07 2019-08-07 라이프 테크놀로지스 코포레이션 Compositions and methods for stabilizing susceptible compounds
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012171031A1 (en) 2011-06-10 2012-12-13 Baxter International Inc. Treatment of coagulation disease by administration of recombinant vwf
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JP2015531244A (en) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Mammalian cell culture method for producing protein
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AR095196A1 (en) * 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SG11201605146VA (en) 2013-12-30 2016-07-28 Baxalta GmbH A method of predicting a performance characteristic of a plant or yeast hydrolysate and its use
CN106282090B (en) * 2015-06-08 2021-07-13 齐鲁制药有限公司 Domesticated CHO-S cell line and culture method and application thereof
TW202340452A (en) 2015-08-04 2023-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
CN105385731B (en) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 A kind of perfusion cultural method of eight factors of expression recombination
EP3299454A1 (en) * 2016-09-21 2018-03-28 Deutsches Krebsforschungszentrum Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium
CN106635953B (en) * 2016-12-13 2021-02-19 昆明润什生物科技有限公司 Serum-free and protein-free cell culture medium
JP6258536B1 (en) 2017-03-03 2018-01-10 協和発酵キリン株式会社 Method for producing darbepoetin composition and method for culturing darbepoetin-producing cells
MX2020000228A (en) * 2017-07-06 2020-08-10 Regeneron Pharma Cell culture process for making a glycoprotein.
EP3648788A1 (en) 2017-07-07 2020-05-13 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
BR112020000322A2 (en) 2017-07-07 2020-07-14 Baxalta Incorporated use of recombinant von willebrand factor (rvwf)
SG11202009213TA (en) 2018-03-21 2020-10-29 Baxalta Inc Separation of vwf and vwf propeptide by chromatographic methods
CN112041674B (en) 2018-04-20 2024-04-02 詹森生物科技公司 Chromatographic column identification in manufacturing methods for preparing anti-TNF antibody compositions
WO2020100073A1 (en) 2018-11-13 2020-05-22 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
MX2021009114A (en) 2019-02-01 2021-10-13 Takeda Pharmaceuticals Co Methods of prophylactic treatment using recombinant vwf (rvwf).
CA3133381A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CA3133395A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
JP2022547556A (en) 2019-09-11 2022-11-14 武田薬品工業株式会社 Therapies involving the complex of von Willebrand factor and complement C1Q
CZ2019606A3 (en) * 2019-09-25 2020-12-16 Výzkumný ústav mlékárenský s.r.o. Hypoallergenic vegan medium for cultivating lactic acid bacteria
KR102519234B1 (en) 2019-12-06 2023-04-10 리제너론 파아마슈티컬스, 인크. Anti-VEGF protein compositions and methods of producing the same
AU2021216945A1 (en) 2020-02-04 2022-09-01 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von Willebrand Disease by administration of recombinant VWF
US20230203469A1 (en) 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
EP4043551A1 (en) 2021-02-12 2022-08-17 Bühler AG Nutrient media for cell culture containing plant protein hydrolysates
KR102392018B1 (en) * 2021-05-24 2022-04-27 한국해양과학기술원 Medium coposition for culturing cells comprising spirulina hydrolysate and preparing method of the same
WO2023281463A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20240034215A (en) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
US20230331776A1 (en) 2022-03-02 2023-10-19 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
WO2024039216A1 (en) * 2022-08-19 2024-02-22 셀미트주식회사 Method for culturing animal cells or animal cell line

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431629A (en) * 1980-05-13 1984-02-14 Novo Industri A/S Method of producing an egg white substitute material
US4443540A (en) * 1980-05-09 1984-04-17 University Of Illinois Foundation Protein hydrolysis
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5316938A (en) * 1990-10-17 1994-05-31 Burroughs Wellcome Co. Defined media for serum-free tissue culture
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
US5393668A (en) * 1991-09-11 1995-02-28 Hans-Wilhelm Doerr Cultivation of mammalian cells in a protein-free medium on a polyvinylformal and/or polyvinyl butyral surface
US5441868A (en) * 1983-12-13 1995-08-15 Kirin-Amgen, Inc. Production of recombinant erythropoietin
US5573937A (en) * 1989-12-07 1996-11-12 Snow Brand Milk Products Co., Ltd. Serum free culture medium
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5741705A (en) * 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US5811299A (en) * 1994-02-08 1998-09-22 Renner; Wolfgang A. Methods for the activation of proliferation of animal cells
US5840719A (en) * 1993-05-28 1998-11-24 Eisai Company, Ltd. Apoptosis inhibitors for treating neurodegenerative diseases
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6100061A (en) * 1997-06-20 2000-08-08 Immuno Aktiengesellschaft Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US6103529A (en) * 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US6372499B1 (en) * 1996-11-15 2002-04-16 I.D.M. Immuno-Designed Molecules Polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US20030203448A1 (en) * 1999-09-28 2003-10-30 Manfred Reiter Medium for the protein-free and serum-free cultivation of cells
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
US20060281820A1 (en) * 2003-02-19 2006-12-14 Kuniyasu Soda Lfa-1 inhibitors and use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT165999B (en) 1947-06-26 1950-05-25 Delle Atel Const Electr Device for protecting three-phase motors against overcurrent
FR2196386A1 (en) * 1972-08-17 1974-03-15 Cudennec Alain Culture media selection - for identification of unknown bacteria
EP0120896B1 (en) 1982-10-02 1986-08-13 Anderson Strathclyde Plc Line pans
JPS59187511A (en) 1983-04-06 1984-10-24 株式会社日本バノツク Automatic bundling machine
FI86885C (en) 1984-04-20 1992-10-26 Genentech Inc Method for Preparation of Human Recombinant Factor VIII and Nucleic Acid Sequences and Vectors Used thereto
DE3688418T2 (en) 1985-02-13 1993-08-26 Scios Nova Inc HUMAN METALLOTHIONEIN II PROMOTOR IN MAMMAL EXPRESSION SYSTEMS.
DE3787805T2 (en) 1986-08-04 1994-02-10 Univ New South Wales Kensingto SERUM-FREE TISSUE CULTURE MEDIUM CONTAINING A POLYMER CELL PROTECTIVE.
WO1989000192A1 (en) 1987-06-30 1989-01-12 Amgen Inc. Production of kallikrein
JP2507882B2 (en) 1988-02-17 1996-06-19 工業技術院長 Method for producing cell line with good growth independent of external growth factor
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
CA2074363C (en) 1990-01-22 2004-11-09 David Thomas Vistica Co2-independent growth medium for maintenance and propagation of cells
JP2844484B2 (en) 1990-02-22 1999-01-06 味の素株式会社 Method for producing recombinant protein
JP2859679B2 (en) 1990-03-01 1999-02-17 協和醗酵工業株式会社 New cell line
JP2696001B2 (en) 1991-04-15 1998-01-14 財団法人化学及血清療法研究所 Medium for recombinant protein production
CA2053433C (en) 1990-10-19 1997-03-25 Michael Joseph Garvey Detergent compositions
JPH04228066A (en) 1990-10-23 1992-08-18 Rikagaku Kenkyusho Culture cell for expressing exogenote
JPH05123178A (en) 1991-11-01 1993-05-21 Ajinomoto Co Inc Production of l-phenylalanine
JPH06217759A (en) 1993-01-25 1994-08-09 Sapporo Breweries Ltd Regeneration of yeast protoplast and culture medium therefor
DE4313620A1 (en) 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamster cell lines and methods for glycoprotein recovery
AU7895898A (en) 1993-04-26 1998-10-08 Hans Wolf Mammal cell lines and method of obtaining glycoproteins
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
JP2766165B2 (en) 1993-08-02 1998-06-18 株式会社バイオポリマー・リサーチ Method for producing bacterial cellulose
WO1996007730A2 (en) 1994-09-09 1996-03-14 Renner Wolfgang A Chemical process for promoting the proliferation of animal cells
ES2323490T3 (en) 1994-11-10 2009-07-17 Baxter Healthcare Sa PROCEDURE OF PRODUCTION OF BIOLOGICAL AGENTS IN A CROP MEANS WITHOUT PROTEINS.
AT403167B (en) 1994-11-14 1997-11-25 Immuno Ag SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
AU4302796A (en) 1994-12-16 1996-07-03 Novartis Ag Production of recombinant secretory component
CA2211630A1 (en) 1995-02-23 1996-08-29 Quest International B.V. Peptides for tissue and cell culture media
AU6125396A (en) 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
AUPN442295A0 (en) 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
DE69838383T2 (en) 1997-05-28 2008-06-05 Novartis Vaccines And Diagnostics S.R.L. CULTURE MEDIUM WITH SOYBEAN EXTRACT AS AN AMINO ACID SOURCE AND NO PROTEIN COMPLEX ANIMAL ORIGIN
ES2273434T3 (en) 1997-07-23 2007-05-01 Roche Diagnostics Gmbh OBTAINING ERYTHROPOYETIN THROUGH GENETIC ACTIVATION ENDOGENA.
FR2775983B1 (en) 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc VIRAL PROPAGATION AND MULTIPLICATION MEDIUM AND METHOD
WO1999057246A1 (en) 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
EP0965583A1 (en) * 1998-06-15 1999-12-22 Transgene S.A. Polyamine compounds and compositions containing them useful for the transfer of active substances into a cell
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AU780810B2 (en) 1999-08-05 2005-04-21 Baxalta GmbH Recombinant stable cell clone, its production and use thereof
NZ529329A (en) 1999-08-25 2005-06-24 Immunex Corp Compositions and methods for improved cell culture
KR100369788B1 (en) 1999-09-03 2003-01-29 동아제약 주식회사 Process for the production of recombinant human erythropoietin
CZ303929B6 (en) * 2000-03-22 2013-07-03 Octapharma Biopharmaceuticals Gmbh Factor VIII mutein, corresponding DNA sequence, vector and host cell, pharmaceutical composition, method of preparing mutein and immortalized human cell line
DE10015688A1 (en) 2000-03-29 2001-10-18 Siemens Ag Method and device for igniting at least one ignition element for a restraint in a motor vehicle
US6596526B1 (en) 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
JP5063852B2 (en) * 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング Live vaccine and production method
EP1208966A1 (en) 2000-11-27 2002-05-29 Cheng-Kun Liao Manufacturing process of patio tabletop glass with broken protection
DE10059175A1 (en) 2000-11-29 2002-06-20 Siemens Ag Method for diverting calls in a communications system with multiple terminals connects to a local area network for activating call rerouting from one terminal to another, for transferring information and for diverting a call.
CA2460206C (en) 2001-10-02 2012-01-24 Novo Nordisk Health Care Ag Method for production of recombinant proteins in eukaryote cells
MXPA05000418A (en) * 2002-07-09 2005-03-23 Baxter Int Animal protein free media for cultivation of cells.
KR20040088169A (en) * 2003-04-09 2004-10-16 주식회사 제일생명공학서비스 Serum-free media for animal cell culture
EP1673452B1 (en) 2003-10-10 2015-12-23 Novo Nordisk Health Care AG Method for large-scale production of a polypeptide in eukaryote cells
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443540A (en) * 1980-05-09 1984-04-17 University Of Illinois Foundation Protein hydrolysis
US4431629A (en) * 1980-05-13 1984-02-14 Novo Industri A/S Method of producing an egg white substitute material
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5441868A (en) * 1983-12-13 1995-08-15 Kirin-Amgen, Inc. Production of recombinant erythropoietin
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
US5250421A (en) * 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5573937A (en) * 1989-12-07 1996-11-12 Snow Brand Milk Products Co., Ltd. Serum free culture medium
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5316938A (en) * 1990-10-17 1994-05-31 Burroughs Wellcome Co. Defined media for serum-free tissue culture
US5633162A (en) * 1990-10-17 1997-05-27 Glaxo Wellcome Inc. Method for culturing Chinese hamster ovary cells
US5393668A (en) * 1991-09-11 1995-02-28 Hans-Wilhelm Doerr Cultivation of mammalian cells in a protein-free medium on a polyvinylformal and/or polyvinyl butyral surface
US5840719A (en) * 1993-05-28 1998-11-24 Eisai Company, Ltd. Apoptosis inhibitors for treating neurodegenerative diseases
US5719050A (en) * 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5811299A (en) * 1994-02-08 1998-09-22 Renner; Wolfgang A. Methods for the activation of proliferation of animal cells
US5789247A (en) * 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5885835A (en) * 1995-02-23 1999-03-23 Quest International Flavors & Food Ingredients Co., Division Of Indopco, Inc. Kit for in vitro cell growth of eucaryotes using low molecular weight peptides containing L-glutamine
US5741705A (en) * 1995-02-23 1998-04-21 Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
US6103529A (en) * 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice
US6372499B1 (en) * 1996-11-15 2002-04-16 I.D.M. Immuno-Designed Molecules Polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US20020182679A1 (en) * 1997-06-20 2002-12-05 Baxter Healthcare Corporation Recombinant cell clones having increased stability and methods of making and using the same
US6100061A (en) * 1997-06-20 2000-08-08 Immuno Aktiengesellschaft Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US6936441B2 (en) * 1997-06-20 2005-08-30 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US7094574B2 (en) * 1997-06-20 2006-08-22 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6537782B1 (en) * 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US20030203448A1 (en) * 1999-09-28 2003-10-30 Manfred Reiter Medium for the protein-free and serum-free cultivation of cells
US20060281820A1 (en) * 2003-02-19 2006-12-14 Kuniyasu Soda Lfa-1 inhibitors and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100011901A1 (en) * 2008-07-16 2010-01-21 Intuitive Surgical, Inc. Four-cable wrist with solid surface cable channels

Also Published As

Publication number Publication date
US20130230919A1 (en) 2013-09-05
PL2213724T3 (en) 2013-02-28
DK2213724T3 (en) 2012-10-15
AU2005299040B2 (en) 2011-07-07
ES2400214T3 (en) 2013-04-08
US20110081722A1 (en) 2011-04-07
US8440408B2 (en) 2013-05-14
US20170267969A1 (en) 2017-09-21
CA2585518A1 (en) 2006-05-04
US20190078051A1 (en) 2019-03-14
PT2213724E (en) 2012-10-09
JP2008517610A (en) 2008-05-29
DK2213725T4 (en) 2024-04-15
WO2006045438A1 (en) 2006-05-04
EP2213725B1 (en) 2012-08-22
US20110081680A1 (en) 2011-04-07
SI2218776T1 (en) 2012-10-30
KR101043547B1 (en) 2011-06-21
DK2213726T3 (en) 2013-01-21
ES2393317T3 (en) 2012-12-20
US20080064080A1 (en) 2008-03-13
DK2213725T3 (en) 2012-09-24
HK1147110A1 (en) 2011-07-29
EP2218776A1 (en) 2010-08-18
CN101065480B (en) 2010-05-26
MX2007005132A (en) 2007-07-04
US10138461B2 (en) 2018-11-27
EP2213726B1 (en) 2012-12-05
PT2213726E (en) 2013-01-22
ES2394746T3 (en) 2013-02-05
US20160083689A1 (en) 2016-03-24
US9222075B2 (en) 2015-12-29
US10655099B2 (en) 2020-05-19
DK2218776T3 (en) 2012-10-15
AU2005299040A1 (en) 2006-05-04
PT2218776E (en) 2012-09-24
EP2218776B1 (en) 2012-08-29
HK1147284A1 (en) 2011-08-05
PL2218776T3 (en) 2013-01-31
ES2393703T3 (en) 2012-12-27
EP2213724B2 (en) 2023-12-27
US20180023048A1 (en) 2018-01-25
CN101065480A (en) 2007-10-31
EP2213725B2 (en) 2024-02-14
US8748156B2 (en) 2014-06-10
US20060094104A1 (en) 2006-05-04
RU2007119719A (en) 2008-12-10
PT2213725E (en) 2012-09-24
US9809796B2 (en) 2017-11-07
RU2383616C2 (en) 2010-03-10
EP2213724B1 (en) 2012-09-26
EP2213724A1 (en) 2010-08-04
US20150104867A1 (en) 2015-04-16
US9714411B2 (en) 2017-07-25
EP1805298A1 (en) 2007-07-11
JP4847962B2 (en) 2011-12-28
PL2213725T3 (en) 2013-01-31
PL2213726T3 (en) 2013-04-30
KR20070073930A (en) 2007-07-10
US20080009040A1 (en) 2008-01-10
EP2213726A1 (en) 2010-08-04
SI2213724T1 (en) 2012-11-30
EP2213725A1 (en) 2010-08-04
SI2213725T1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
US10655099B2 (en) Animal protein-free media for cultivation of cells
US9758568B2 (en) Oligopeptide-free cell culture media
AU2011221414B2 (en) Animal Protein-Free Media for Cultivation of Cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER INTERNATIONAL INC.,ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRILLBERGER, LEOPOLD;REITER, MANFRED;MUNDT, WOLFGANG;AND OTHERS;SIGNING DATES FROM 20050329 TO 20050413;REEL/FRAME:024578/0613

Owner name: BAXTER HEALTHCARE S.A.,SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRILLBERGER, LEOPOLD;REITER, MANFRED;MUNDT, WOLFGANG;AND OTHERS;SIGNING DATES FROM 20050329 TO 20050413;REEL/FRAME:024578/0613

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRILLBERGER, LEOPOLD;REITER, MANFRED;MUNDT, WOLFGANG;AND OTHERS;SIGNING DATES FROM 20050329 TO 20050413;REEL/FRAME:024578/0613

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRILLBERGER, LEOPOLD;REITER, MANFRED;MUNDT, WOLFGANG;AND OTHERS;SIGNING DATES FROM 20050329 TO 20050413;REEL/FRAME:024578/0613

AS Assignment

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: CHANGE OF ADDRESS FOR ONE ASSIGNEE (ATTACHMENT NOT REQUIRED);ASSIGNOR:BAXTER HEALTHCARE SA.;REEL/FRAME:024833/0048

Effective date: 20100805

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION